Targeted therapies for ER+/HER2- metastatic breast cancer

The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine res...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto-Ibusuki, Mutsuko, Arnedos, Monica, André, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462184/
https://www.ncbi.nlm.nih.gov/pubmed/26059247
http://dx.doi.org/10.1186/s12916-015-0369-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462184/
https://www.ncbi.nlm.nih.gov/pubmed/26059247
http://dx.doi.org/10.1186/s12916-015-0369-5

Ejemplares similares